Scarica l'app Stockscreener
54.55
0.87%
0.47
Dopo l'orario di chiusura:
54.55
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Precedente Chiudi:
$54.08
Aprire:
$53.89
Volume 24 ore:
2.42M
Relative Volume:
0.93
Capitalizzazione di mercato:
$13.52B
Reddito:
$2.38B
Utile/perdita netta:
$833.42M
Rapporto P/E:
18.08
EPS:
3.0172
Flusso di cassa netto:
$917.69M
1 W Prestazione:
+4.26%
1M Prestazione:
-1.48%
6M Prestazione:
+20.85%
1 anno Prestazione:
+41.21%
Intervallo 1D:
$53.39
$54.79
Intervallo di 1 settimana:
$52.11
$54.79
Portata 52W:
$33.76
$57.57
Exelixis Inc Stock (EXEL) Company Profile
Nome
Exelixis Inc
Settore
Industria
Telefono
(650) 837-7000
Indirizzo
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
54.55 | 13.30B | 2.38B | 833.42M | 917.69M | 3.0172 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-11-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Iniziato | Goldman | Buy |
| 2025-07-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2024-09-19 | Iniziato | UBS | Neutral |
| 2024-04-11 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Iniziato | BTIG Research | Buy |
| 2023-12-15 | Iniziato | Citigroup | Buy |
| 2023-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-22 | Reiterato | Oppenheimer | Outperform |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Ripresa | Piper Sandler | Overweight |
| 2023-03-09 | Iniziato | Wells Fargo | Overweight |
| 2023-01-26 | Iniziato | Credit Suisse | Outperform |
| 2022-10-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-03 | Ripresa | Jefferies | Buy |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-18 | Ripresa | Goldman | Sell |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-03-18 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Iniziato | Goldman | Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Underweight |
| 2018-05-11 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-16 | Reiterato | SunTrust | Buy |
| 2017-09-22 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-09-12 | Reiterato | Needham | Buy |
| 2017-07-14 | Iniziato | SunTrust | Buy |
| 2017-03-31 | Iniziato | Needham | Buy |
| 2017-03-16 | Iniziato | Oppenheimer | Perform |
| 2017-02-28 | Downgrade | Stifel | Buy → Hold |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2016-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Reiterato | Stifel | Buy |
Mostra tutto
Exelixis Inc Borsa (EXEL) Ultime notizie
NFJ Investment Group LLC Makes New $18.39 Million Investment in Exelixis, Inc. $EXEL - MarketBeat
51,642 Shares in Exelixis, Inc. $EXEL Purchased by NewEdge Wealth LLC - MarketBeat
BlackRock Inc. Purchases New Stake in Exelixis, Inc. $EXEL - MarketBeat
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law - The Daily Tribune News
FARALLON CAPITAL MANAGEMENT, L.L.C. Buys More Exelixis Inc (EXEL - GuruFocus
BMO Capital Markets Upgrades Exelixis (NASDAQ:EXEL) to "Hold" - MarketBeat
Abacus FCF Advisors LLC Invests $7.29 Million in Exelixis, Inc. $EXEL - MarketBeat
Out of sight, out of work? What’s driving remote job cuts - BioSpace
Investigation launched into EXELIXIS officers f... - Pluang
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm - PR Newswire
Exelixis Inc : BMO Initiates Coverage With Ma - Moomoo
EXELIXIS INC : BMO INITIATES COVERAGE WITH MARKET PERFORM RATING; PRICE TARGET $54 - Bitget
BMO initiates Exelixis stock at Market Perform, cites patent cliff By Investing.com - Investing.com Australia
EXEL Initiates Coverage On BMO Capital -- Price Target Announced at $54.00 - GuruFocus
BMO initiates Exelixis stock at Market Perform, cites patent cliff - Investing.com
JLB & Associates Inc. Acquires Shares of 48,849 Exelixis, Inc. $EXEL - MarketBeat
Exelixis Inc (EXEL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AQR Capital Management Trims Exelixis Inc (EXEL) Stake -- Shares Trade 16% Above GF Value - GuruFocus
EXEL Looks 16.3% Overvalued on GF Value™ - GuruFocus
Pallas Capital Advisors LLC Invests $1.67 Million in Exelixis, Inc. $EXEL - MarketBeat
27,109 Shares in Exelixis, Inc. $EXEL Purchased by Grandfield & Dodd LLC - MarketBeat
Exelixis (EXEL) Climbs 2.48% as Shares Test Key Resistance at $55.14ATR Stop - vinanet.vn
Exelixis (EXEL) Securities Investigation NoticeLevi & Korsinsky - PR Newswire
Exelixis, Inc. (EXEL) Stock Analysis: Evaluating the 3.31% Upside with Strong Revenue Growth - DirectorsTalk Interviews
Focus Partners Advisor Solutions LLC Buys Shares of 26,603 Exelixis, Inc. $EXEL - MarketBeat
Exelixis (MIC:EXEL-RM) EV-to-OCF : 0.00 (As of Aug. 16, 2026) - GuruFocus
Exelixis (EXEL) Is Down 5.2% After Raising Q2 Profitability And Trimming 2026 Revenue Outlook – Has The Bull Case Changed? - Sahm
EXEL|Exelixis Inc|Price:50.990| - TradingKey
Farallon Capital (EXEL) discloses 13.99M-share Exelixis stake at $308M cost - Stock Titan
EXEL|Exelixis Inc|Price:52.360|Chg%:+1.120 - TradingKey
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Exelixis (EXEL) - GlobeNewswire
Exelixis Inc (EXEL) Director Mary Beckerle Sells 9,812 Shares - GuruFocus
Annex Advisory Services LLC Makes New Investment in Exelixis, Inc. $EXEL - MarketBeat
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo! Finance Canada
Exelixis director Mary Beckerle sells $526k in shares - Investing.com
Exelixis director Mary Beckerle sells $526k in shares By Investing.com - Investing.com South Africa
Insider Selling: Exelixis (NASDAQ:EXEL) Director Sells $526,511.92 in Stock - MarketBeat
Exelixis (EXEL) Q2 2026 Earnings Call Transcript - The Globe and Mail
Exelixis (EXEL) director Beckerle sells 9,812 shares via Rule 10b5-1 plan - Stock Titan
EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL) - Business Wire
AQR Capital discloses 11.0M-share Exelixis (EXEL) position at 4.39% ownership - Stock Titan
EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Exelixis - PR Newswire
Exelixis Inc (EXEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Exelixis Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Exelixis (EXEL) - PR Newswire
EXELIXIS, INC. SEC Filing (Aug 10, 2026) - stocktitan.net
Exelixis, Inc. (EXEL) Stock Analysis: Exploring Growth Potential in Oncology with a Strong ROE - DirectorsTalk Interviews
Bank of America Corp DE Sells 578,181 Shares of Exelixis, Inc. $EXEL - MarketBeat
Exelixis, Inc. $EXEL Shares Acquired by Assenagon Asset Management S.A. - MarketBeat
EXELIXIS INCDRN (E2XE34.SA) Q1 FY2026 earnings call transcript - Yahoo Finance
Amundi Sells 121,348 Shares of Exelixis, Inc. $EXEL - MarketBeat
Exelixis (NASDAQ:EXEL) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
Exelixis Inc Azioni (EXEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
3.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):